Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by University of Pittsburgh.
Recruitment status was  Recruiting
Sponsor:
Collaborator:
Novartis
Information provided by:
University of Pittsburgh
ClinicalTrials.gov Identifier:
NCT00336895
First received: June 12, 2006
Last updated: October 2, 2008
Last verified: October 2008

June 12, 2006
October 2, 2008
November 2006
November 2008   (final data collection date for primary outcome measure)
  • Incidence and severity of GI adverse events [ Time Frame: 2, 6 and 12 weeks ] [ Designated as safety issue: Yes ]
  • incidence and severity of bone marrow suppression (leukopenia) [ Time Frame: 2, 6 and 12 weeks ] [ Designated as safety issue: Yes ]
  • incidence of cytomegalovirus infection or disease [ Time Frame: 2, 6 and 12 weeks ] [ Designated as safety issue: Yes ]
  • Incidence and severity of GI adverse events
  • incidence and severity of bone marrow suppression (leukopenia)
  • incidence of cytomegalovirus infection or disease
Complete list of historical versions of study NCT00336895 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Conversion of CellCept to Myfortic: A Prospective Study in Liver Transplant Recipients
Conversion of CellCept to Myfortic: A Prospective Study on the Tolerability and Safety of Myfortic in Liver Transplant Recipients

The objective of this study is to determine the tolerability and safety of Myfortic in liver transplant patients. Patients receiving CellCept who have GI side effects will have CellCept discontinued and changed to Myfortic (Myfortic is a new drug similar to CellCept, except it is enteric-coated). Our hypothesis is that Myfortic has less GI side effects and will, therefore, be tolerated better than CellCept and also that Myfortic will have a comparable effectiveness to CellCept.

This is a prospective, single center, open-label, safety and tolerability study on the use of Myfortic after liver transplantation. Adult liver transplant patients who are experiencing GI symptoms (nausea, vomiting, diarrhea, abdominal discomfort/pain, dyspepsia) attributable to CellCept are eligible to enter the study. CellCept will be discontinued and replaced with Myfortic. The duration of the study will be 3 months, and during this time, we will assess the incidence and severity of GI adverse events, the incidence and severity of bone marrow suppression (leukopenia), and the incidence of cytomegalovirus (CMV) infection or disease in patients receiving Myfortic.

Interventional
Not Provided
Allocation: Non-Randomized
Endpoint Classification: Safety Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Immunosuppression
Drug: Myfortic
Myfortic 360mg or 720 mg BID for 90 days.
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
30
November 2008
November 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • ALL patients will be adult liver transplant recipients, males or females, 18-80 years of age
  • Patients currently receiving tacrolimus or cyclosporine with or without corticosteroids as part of their immunosuppressive regimen
  • Patients must be receiving CellCept and must have attributable G.I. symptoms (nausea, vomiting, diarrhea, abdominal discomfort/pain, dyspepsia)
  • Patients must be more than 30 days post-transplant to be eligible
  • Females of childbearing potential must have a negative serum pregnancy test prior to the inclusion period

Exclusion Criteria:

  • Multi-organ transplant patients
  • HIV positive patients.
  • Living-related liver transplant recipients
  • Pregnant patients
  • Patients with a history of extra-hepatic malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin
  • Patients with thrombocytopenia (<50,000/mm3), with an absolute neutrophil count of <1,000/mm3 and/or leukocytopenia (<2,000/mm3), and/or hemoglobin <7.0 g/dL prior to enrollment
  • Patients with a G.I. clinical problem at the time of enrollment (e.g. CMV infection or disease, C. difficile colitis, active peptic ulcer disease, gastroenteritis, inflammatory bowel disease)
  • Presence of clinically significant infection requiring continued therapy or uncontrolled diabetes mellitus
  • Evidence of drug and/or alcohol abuse
  • Decisionally impaired subjects who are not medically or mentally capable of providing consent themselves
Both
18 Years to 80 Years
No
Contact: Michael E de Vera, MD 412-647-5174 deverame@upmc.edu
Contact: Laurie K Hope, RN 412-692-2208 hopelk@upmc.edu
United States
 
NCT00336895
CERL080A-US27
Yes
Michael de Vera, M.D., UPMC
University of Pittsburgh
Novartis
Principal Investigator: Michael E de Vera, MD University of Pittsburgh
University of Pittsburgh
October 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP